# Protamine Sulfate During Transcatheter Aortic Valve Implantation

Study · id `cardio:ct-nct02974660` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02974660](<https://clinicaltrials.gov/study/NCT02974660>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02974660

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 100 participants.

## Technical summary

Registry record NCT02974660. Randomized; single masking; primary purpose prevention. Start 2016-12 (registry gives no type); primary completion 2020-07 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 100 participants (enrolled count; ClinicalTrials.gov record NCT02974660, source copy `cardio:ctgov-nct02974660-2020-10-22`, retrieved 2026-10-26)
- Start date: 2016-12 (registry gives no type) (ClinicalTrials.gov record NCT02974660, source copy `cardio:ctgov-nct02974660-2020-10-22`, retrieved 2026-10-26)
- Primary completion: 2020-07 (actual) (ClinicalTrials.gov record NCT02974660, source copy `cardio:ctgov-nct02974660-2020-10-22`, retrieved 2026-10-26)
- Completion: 2020-09 (actual) (ClinicalTrials.gov record NCT02974660, source copy `cardio:ctgov-nct02974660-2020-10-22`, retrieved 2026-10-26)
- Countries: Poland (ClinicalTrials.gov record NCT02974660, source copy `cardio:ctgov-nct02974660-2020-10-22`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02974660-2020-10-22`, retrieved 2026-10-26)

## The registry's words

- Brief title: Protamine Sulfate During Transcatheter Aortic Valve Implantation
- Acronym: PS TAVI
- Condition: Aortic Valve Stenosis
- Intervention (Drug): Protamine sulfate
- Intervention (Drug): 0.9% NaCl
- Lead sponsor: Medical University of Warsaw
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Aortic stenosis (`cardio:aortic-stenosis`)
- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry lists this organization as the lead sponsor: Medical University of Warsaw (`cardio:org-medical-university-of-warsaw`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Protamine sulfate during transcatheter aortic valve implantation (PS TAVI) - a single-center, single-blind, randomized placebo-controlled trial (`cardio:pubmed-34292562`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: ccdcf97ece463dfd308efa39fd9f890d253649d9b44b8d274ef5c703e219f1f9
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
